BTIG Reiterates Buy on Mereo BioPharma Group, Maintains $6 Price Target

Benzinga · 2d ago
BTIG analyst Julian Harrison reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $6 price target.